Autolus Therapeutics plc - ADR earnings per share and revenue
On Nov 12, 2025, AUTL reported earnings of -0.30 USD per share (EPS) for Q3 25, missing the estimate of -0.23 USD, resulting in a -30.32% surprise. Revenue reached 21.14 million, compared to an expected 21.74 million, with a -2.73% difference. The market reacted with a -9.33% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 10 analysts forecast an EPS of -0.26 USD, with revenue projected to reach 25.27 million USD, implying an decrease of -13.33% EPS, and increase of 19.53% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
FAQ
What were Autolus Therapeutics plc - ADR's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Autolus Therapeutics plc - ADR reported EPS of -$0.30, missing estimates by -30.32%, and revenue of $21.14M, -2.73% below expectations.
How did the market react to Autolus Therapeutics plc - ADR's Q3 2025 earnings?
The stock price moved down -9.33%, changed from $1.50 before the earnings release to $1.36 the day after.
When is Autolus Therapeutics plc - ADR expected to report next?
The next earning report is scheduled for Mar 18, 2026.
What are the forecasts for Autolus Therapeutics plc - ADR's next earnings report?
Based on 10
analysts, Autolus Therapeutics plc - ADR is expected to report EPS of -$0.26 and revenue of $25.27M for Q4 2025.